Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aprepitant for PONV Prevention in High-risk Outpatient Surgery
NCT07248280Phase 3Completed
- Sponsor
- Centre hospitalier de l’Université de Montréal
- Start
- Feb 2026
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of aprepitant in postoperative nausea and vomiting (PONV), sponsored by Centre hospitalier de l’Université de Montréal. Started Feb 2026; status: completed.
02
Drugs
aprepitant
03
Conditions
postoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on NCT07248280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07248280.